A previous study has clarified that bufalin, one of active bufadienolide compounds with similar chemical structure with Helle and Areno, can function as a SRC-3 inhibitor by directly binding to SRC-3 in its receptor interacting domain and selectively promoting SRC-3 protein degradation in ER-positive breast cancer cell lines (40). The gene discussed is NCOA3; the disease is breast cancer.